ProPhase Labs Stockholders Approve All Proposals at September 9, 2025 Special Meeting By More Than 75% In Favor

Core Points - ProPhase Labs stockholders approved all proposals at the Special Meeting on September 9, 2025, with each proposal receiving over 75% support, allowing the company to proceed with strategic initiatives, including increasing authorized shares to 1 billion [1][3] - The Board of Directors was re-elected with over 90% support at the June annual meeting [2] - The increase in authorized shares is intended to provide resources for strategic opportunities, including a potential crypto treasury strategy and the development of current subsidiaries [3] - The company plans to update stockholders on positive developments regarding the Crown Medical Collections initiative, which aims to net up to $50 million in Covid accounts receivables, and the commercialization of the BE-Smart Esophageal Cancer Test [4] Company Overview - ProPhase Labs Inc. is a next-generation biotech, genomics, and consumer products company focused on healthcare innovation through Whole Genome Sequencing solutions and diagnostic development [5] - The company aims to revolutionize healthcare and is committed to executional excellence, smart diversification, and a synergistic approach to its operations [5]